Phase 3, Open-Label Multicenter Study of Sotatercept in Japanese Participants With Pulmonary Arterial Hypertension
{{output}}
Background: Sotatercept is a first-in-class activin signaling inhibitor, developed for the treatment of pulmonary arterial hypertension (PAH). Objectives: ... ...
